The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Smith Jason Drew since 2021.
This trader's CIK number is 1821479.
At the time of last reporting, Smith Jason Drew was the General Counsel of Urogen Pharma Ltd.. (stock ticker symbol URGN).
Also see all insider trading activities at Urogen Pharma Ltd..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | URGN | 0 | $0 | 14,901 | $226,173 | 31,167 | $0 |
| 2024 | URGN | 0 | $0 | 6,514 | $98,483 | 13,333 | $0 |
| 2023 | URGN | 0 | $0 | 5,436 | $84,994 | 11,667 | $0 |
| 2022 | URGN | 0 | $0 | 4,020 | $29,137 | 9,166 | $0 |
| 2021 | URGN | 2,500 | $39,275 | 3,803 | $45,750 | 8,333 | $0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-07-28 | URGN | Option Ex | 16,500 | .00 | 0 |
| 2025-07-28 | URGN | Sale | 7,522 | 19.14 | 143,971 |
| 2025-01-31 | URGN | Sale | 7,379 | 11.14 | 82,202 |
| 2025-01-31 | URGN | Option Ex | 14,667 | .00 | 0 |
| 2024-09-09 | URGN | Option Ex | 3,333 | .00 | 0 |
| 2024-09-09 | URGN | Sale | 1,521 | 13.08 | 19,894 |
| 2024-01-31 | URGN | Option Ex | 10,000 | .00 | 0 |
| 2024-01-31 | URGN | Sale | 4,993 | 15.74 | 78,589 |
| 2023-08-31 | URGN | Option Ex | 8,334 | .00 | 0 |
| 2023-08-31 | URGN | Sale | 3,800 | 18.01 | 68,438 |
| 2023-01-31 | URGN | Option Ex | 3,333 | .00 | 0 |
| 2023-01-31 | URGN | Sale | 1,636 | 10.12 | 16,556 |
| 2022-08-31 | URGN | Option Ex | 8,333 | .00 | 0 |
| 2022-08-31 | URGN | Sale | 3,606 | 7.21 | 25,999 |
| 2022-01-31 | URGN | Option Ex | 833 | .00 | 0 |
| 2022-01-31 | URGN | Sale | 414 | 7.58 | 3,138 |
| 2021-11-30 | URGN | Option Ex | 8,333 | .00 | 0 |
| 2021-11-30 | URGN | Sale | 3,803 | 12.03 | 45,750 |
| 2021-05-17 | URGN | Buy | 2,500 | 15.71 | 39,275 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Smith Jason Drew (General Counsel of Urogen Pharma Ltd. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.